Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease - Wikidata - awgldk - TriplyDB

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease

http://www.wikidata.org/entity/Q35540628

about

Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics Checkpoints to the Brain: Directing Myeloid Cell Migration to the Central Nervous System A vaccine with Aβ oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimer's disease A retrospective analysis of the Alzheimer's disease vaccine progress - The critical need for new development strategies.Future Therapeutics in Alzheimer's Disease: Development Status of BACE Inhibitors.A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease.Design of virus-based nanomaterials for medicine, biotechnology, and energy.Amyloid-beta immunotherapy: the hope for Alzheimer disease?Developing therapeutic vaccines against Alzheimer's disease.Virus-based nanoparticles as platform technologies for modern vaccines.The Amyloid Cascade Hypothesis in Alzheimer's Disease: It's Time to Change Our Mind.Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies.Improving Memory and Cognition in Individuals with Down Syndrome.Immunotherapies for neurodegenerative diseases: current status and potential of plant-made biopharmaceuticals.The road to restoring neural circuits for the treatment of Alzheimer's disease.Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: A Systematic Review and Meta-Analysis.Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer's Disease.Nature Versus Nurture: Does Proteostasis Imbalance Underlie the Genetic, Environmental, and Age-Related Risk Factors for Alzheimer's Disease?UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer's disease.Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study.The past, present, and future of disease-modifying therapies for Alzheimer's disease.Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise.Escherichia coli-derived virus-like particles in vaccine development.Efficacy and safety of anti-amyloid-β immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis.Vaccination strategies in tauopathies and synucleinopathies.Impact of amyloid-beta changes on cognitive outcomes in Alzheimer's disease: analysis of clinical trials using a quantitative systems pharmacology model.Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial.Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.Prospects for strain-specific immunotherapy in Alzheimer's disease and tauopathies.Phyto-Therapeutic and Nanomedicinal Approaches to Cure Alzheimer's Disease: Present Status and Future Opportunities

P2860

Q26738355-D1F2E994-2041-4132-8E44-B14ADE3BDC80 Q26740189-6D96E1C2-E7C4-44B5-B082-D1990F4B43D1 Q26745928-26B4F74D-A930-4E7B-9E0C-99E7787A46E1 Q26784569-A8D3CAA0-FFA3-47C1-BFD9-3CABE84B7432 Q28066906-D3DC2B60-92D8-4A84-9321-98CB550DF3D8 Q33771800-6AE5A9A7-E599-4148-ADD4-626BB59320CE Q34518856-88DA2FEE-1EBA-4684-A178-D648162D7C0D Q35972878-58E59978-06DF-47EB-97BD-DB9F70F67AA6 Q36240389-25391C76-5228-43E5-A5D7-77557EB6EFD8 Q37346447-DB932729-3B3D-4B12-A4FF-CA762E4C4455 Q37679265-A0AC91C5-B5F5-40E8-97DA-DB831938C290 Q38636151-EDEB0AEF-CBD7-42FE-A6FF-251EB9AACB6A Q38702017-1871DDFD-4032-4E18-9E2B-FB538D1E28C0 Q38769710-6427495D-9B8F-47B0-AC48-1A7499D457F9 Q38802634-7561EE5B-2CCF-476D-BD16-3E862CB2359A Q38858096-6FC80ACF-342C-4AE2-8285-35AB58DF643C Q38942195-7894EBB1-D8D8-4DED-888C-AE383CC2F2AB Q39004340-C0597F56-8A02-41AD-80C4-A7997537E03B Q39057175-834B35E9-4B61-4B33-9CA2-EBAE75A36592 Q41248630-AE7353FF-3489-45CA-8DF7-1947E09BE6FD Q41665563-A37659C4-76D3-491F-A68A-1C9FB5862B48 Q42655652-2CB2E4F4-1EEC-4404-872B-C9AE3E94F04C Q42656077-A11931DF-8BDE-4AE9-A031-8E101D057117 Q46244313-B4A26E2B-A399-426B-9A43-6DBCAE6A9B35 Q46297382-7AE3F30A-B71C-4AA5-B442-8E0F4F62ED84 Q47132009-2ED065CF-D140-4E85-857C-4CDF4703D683 Q47138749-E2DB8B0C-5F54-4A60-BA63-4D817399F9C6 Q47860105-9F58FFD7-8207-4F8A-B554-2092C88B8E59 Q48113629-A78A9B49-9BE3-48A7-9512-9AF69211D513 Q48520500-1FA3782B-5765-4542-A245-0DFA9D1650E3 Q48842824-0E8903DE-81A6-41D2-8F1E-BE0C28A4A52C Q50532471-6B9816C1-7AB0-46C1-856D-1A2EFF82FFC3 Q58571824-41887480-876A-4926-8C42-32DB69ED289C

P2860

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease

http://www.wikidata.org/entity/Q35540628

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease

@ast

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease

@en

type

label

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease

@ast

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease

@en

prefLabel

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease

@ast

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease

@en

P1433

Q35540628-CBE78B37-E53A-43ED-9374-B1ED6345B699

P1476

Q35540628-804B80A7-DB08-4369-91F4-948E5DD485AC

P2093

Q35540628-3F35FD2B-AA3F-4FF9-AB54-DF4B09F9968E

Q35540628-5719FD3B-217F-47AE-93D2-2319FC09FC88

Q35540628-76AB8AD5-E552-40C9-8CE8-4D3B71366F4F

Q35540628-975DEE86-672F-406E-B1A9-7758BAA0FDB0

Q35540628-ACEC0C3D-95AA-498A-8EE9-47AFE4B25E41

Q35540628-CE298135-3269-400C-AFE9-D4FB31CA6D10

Q35540628-E4EE7509-925B-4A74-A7CE-ABAD6978F5FE

Q35540628-E86B7983-12E5-4C65-BDA7-97B44EA7DFCE

P2860

Q35540628-0DC5F2D3-7B6B-40B9-B707-AB36794006BF

Q35540628-0F34F851-D1B9-4BA8-B8BC-8EC286AC4BAB

Q35540628-15B82AFC-38D3-48D8-8ADC-72D333858B7B

Q35540628-24155733-3F15-4E74-80C5-6048CD4C7B8B

Q35540628-28B0479B-421D-4801-9B2F-FF8970B27DAC

Q35540628-37FBFAB2-AE2C-4E49-BE83-36B19979EA51

Q35540628-399E2BC0-5457-4D47-86EA-2A918B703CB3

Q35540628-3E1204D2-7F26-4523-A889-3A1FAEFAE1B8

Q35540628-42B8E95F-D468-4F73-BDE8-6E46BEC927BD

Q35540628-4A07CC33-6EA2-48AB-B272-022A50B291C5

P2888

Q35540628-B29EAD7F-00D8-4BC6-8B22-F783DA847DC9

P304

Q35540628-79700EF2-71A0-4DBE-86F1-EE45DF817BB6

P31

Q35540628-22737FFA-A3F3-4E5B-B064-370EB5D25108

P356

Q35540628-7DB21B11-8A35-480B-9953-AF07CB43C8A5

P407

Q35540628-2A0259F1-CF0F-4A94-A199-0964E7A4DC17

P433

Q35540628-434534C4-DDE9-4141-8694-66C31BE9A47A

P478

Q35540628-91611873-4BA9-4270-9FB7-E704ACCFBEE9

P50

Q35540628-07F68693-4C1B-4B35-B673-9A5FADD12367

P577

Q35540628-2BBA9DA0-5940-48A8-8FC7-B6CF06C18C4A

P5875

Q35540628-AB59690A-F572-44EA-BB08-AFC37C7931A3

P6179

Q35540628-07FAF1F9-F88B-4BB9-80B0-513C097D726A

P698

Q35540628-F5D57C79-B0A3-4BC0-B07F-DB55376355EA

P921

Q35540628-4EF99D44-AA58-4A84-BF35-F4780063D596

Q35540628-615FE970-5B8F-4209-B21C-FFB6E7A91E1C

P932

Q35540628-850A8DC9-6F28-4998-BE72-47133553F923

P356

S13195-015-0108-3

P1433

Alzheimers Research & Therapy

P1476

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease

@en

P2093

Alessandra Vitaliti

http://www.w3.org/2001/XMLSchema#string

Ana Graf

http://www.w3.org/2001/XMLSchema#string

Angelika Caputo

http://www.w3.org/2001/XMLSchema#string

Igor Vostiar

http://www.w3.org/2001/XMLSchema#string

Judit Sovago

http://www.w3.org/2001/XMLSchema#string

Marie-Emmanuelle Riviere

http://www.w3.org/2001/XMLSchema#string

Martin R Farlow

http://www.w3.org/2001/XMLSchema#string

Niels Andreasen

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.

Total and phosphorylated tau protein as biological markers of Alzheimer's disease.

Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.

Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.

P2888

s13195-015-0108-3

P304

23

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13195-015-0108-3

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275586004

http://www.w3.org/2001/XMLSchema#string

P6179

1032001916

http://www.w3.org/2001/XMLSchema#string

P698

25918556

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

4410460

http://www.w3.org/2001/XMLSchema#string